Hunan Cancer Hospital

JMT103 Demonstrates Efficacy in Unresectable Giant Cell Tumor of Bone

7 months ago

• JMT103, a novel therapy, shows promising efficacy in treating unresectable or surgically-challenging giant cell tumor of bone (GCTB). • The Phase Ib/II study demonstrated a notable objective tumor response rate (OTR) based on histopathological or radiological evaluation. • Treatment with JMT103 led to clinically meaningful reductions in pain and improvements in daily functioning for GCTB patients. • The safety profile of JMT103 was manageable, with adverse events consistent with the mechanism of action and manageable with supportive care.

SHR-A1921 Shows Promise in Platinum-Resistant Ovarian Cancer

7 months ago

• SHR-A1921, an antibody-drug conjugate, demonstrated a 42.3% overall response rate in platinum-resistant ovarian cancer patients at a 3.0 mg/kg dose. • The disease control rate reached 100% in patients treated with SHR-A1921 at 3.0 mg/kg, with a median duration of response of 9.9 months. • Manageable safety profiles were observed across both 3.0 mg/kg and 2.0 mg/kg dosing regimens of SHR-A1921 in heavily pretreated patients. • A phase 3 trial is underway to compare SHR-A1921 with chemotherapy in platinum-resistant epithelial ovarian cancer.